Featured Publications
Longitudinal Trajectories of Multiple Nicotine Product Use Among Youths in the Population Assessment of Tobacco and Health Study
Simon P, Jiang Y, Buta E, Sartor CE, Krishnan-Sarin S, Gueorguieva R. Longitudinal Trajectories of Multiple Nicotine Product Use Among Youths in the Population Assessment of Tobacco and Health Study. JAMA Network Open 2022, 5: e223549. PMID: 35319763, PMCID: PMC8943628, DOI: 10.1001/jamanetworkopen.2022.3549.Peer-Reviewed Original ResearchConceptsNicotine product useCigar useTobacco usersTobacco useHealth StudyCigarette useProduct useWave 1Significant public health concernLongitudinal trajectoriesPublic health concernNon-Hispanic whitesTobacco product useLogistic regression modelsTobacco use behaviorsComplex survey designMultinomial logistic regression modelsDays of useSocioecological factorsMAIN OUTCOMESmokeless tobaccoLower oddsNicotine productsLatent class growth analysisSociodemographic factorsTrajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis
Gueorguieva R, Chekroud AM, Krystal JH. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. The Lancet Psychiatry 2017, 4: 230-237. PMID: 28189575, PMCID: PMC5340978, DOI: 10.1016/s2215-0366(17)30038-x.Peer-Reviewed Original ResearchConceptsActive medicationActive treatmentClinical trialsDepression severityHamilton Depression Rating Scale scoresDepression Rating Scale scoresClinical Global Impression scoresIndividual patient-level dataDouble-blind treatmentPlacebo-controlled trialPatterns of relapseGlobal Impression scoresIndividual patient dataPrevention of relapseTrajectory class membershipTreatment of depressionMajor depressive disorderRating Scale scoresPatient-level dataPost-traumatic stress disorderTreatment discontinuationAntidepressant treatmentClinical responseAlcohol Research CenterAntidepressant medicationTemporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response
Gueorguieva R, Wu R, Krystal JH, Donovan D, O'Malley SS. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addictive Behaviors 2013, 38: 2119-2127. PMID: 23435273, PMCID: PMC3595348, DOI: 10.1016/j.addbeh.2013.01.024.Peer-Reviewed Original ResearchConceptsPercent heavy drinking daysAdherence trajectoriesExcellent adherersPercent days abstinentPatient characteristicsMedication adherenceTreatment outcomesMedication adherence trajectoriesPatterns of treatmentHeavy drinking daysPatterns of adherenceExcellent medication adherenceLack of benefitTrajectories of adherenceIntervention main effectsActive medicationAdverse eventsPharmacologic treatmentHigher percent days abstinentTreatment adherenceTreatment modalitiesWorse outcomesTreatment responseDays abstinentDrinking daysCross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, Cannon TD, Krystal JH, Corlett PR. Cross-trial prediction of treatment outcome in depression: a machine learning approach. The Lancet Psychiatry 2016, 3: 243-250. PMID: 26803397, DOI: 10.1016/s2215-0366(15)00471-x.Peer-Reviewed Original ResearchConceptsTreatment outcomesTreatment groupsEscitalopram treatment groupSpecific antidepressantsPatient-reported dataSequenced Treatment AlternativesClinical trial dataIndependent clinical trialsClinical remissionSymptomatic remissionClinical trialsTreatment efficacyPatientsProspective identificationTreatment alternativesTrial dataDepressionRemissionAntidepressantsOutcomesGroupLevel 1CitalopramCohortClinicians
2024
Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial
Horvath M, Pittman B, O’Malley S, Grutman A, Khan N, Gueorguieva R, Brewer J, Garrison K. Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial. Annals Of Medicine 2024, 56: 2352803. PMID: 38823419, PMCID: PMC11146247, DOI: 10.1080/07853890.2024.2352803.Peer-Reviewed Original ResearchConceptsBrief mindfulness interventionsMindfulness exercisesTreatment startersMindfulness interventionSmoking interventionsOnline mindfulness trainingWhite non-HispanicMindfulness trainingTreatment fidelityFeasibility measuresHelpfulness ratingsNon-HispanicDaily smokersPredicting smokingReduce smokingExerciseSmokingCigarette smokingInterventionLow completenessAdherenceParticipantsSmartbandAcceptanceMindfulnessA randomized controlled trial of potential tobacco policies prohibiting menthol flavor in cigarettes and e-cigarettes: a study protocol
Bold K, Sharma A, Haeny A, Gueorguieva R, Buta E, Baldassarri S, Lempert L, Krishnan-Sarin S, O’Malley S. A randomized controlled trial of potential tobacco policies prohibiting menthol flavor in cigarettes and e-cigarettes: a study protocol. BMC Psychiatry 2024, 24: 201. PMID: 38475757, PMCID: PMC10935798, DOI: 10.1186/s12888-024-05619-0.Peer-Reviewed Original ResearchConceptsSmoking menthol cigarettesE-cigarettesCigarette useReduce tobacco-related health disparitiesTobacco-related health disparitiesMenthol cigarettesRates of menthol cigarette useTobacco use statusMenthol cigarette useRandomized controlled trialsPublic health problemHealth disparitiesTobacco policiesFlavored e-cigarettesSmoke-freeMenthol flavorsMenthol policiesBlack adultsQuit smokingNon-Black participantsSmoking behaviorFollow-up visitHealth problemsSecondary outcomesE-cigarette products
2023
Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlaceboCognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial
Grilo C, Lydecker J, Gueorguieva R. Cognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial. International Journal Of Eating Disorders 2023, 56: 1544-1553. PMID: 37144325, PMCID: PMC10524840, DOI: 10.1002/eat.23975.Peer-Reviewed Original ResearchConceptsInitial acute treatmentBinge-eating disorderCognitive behavioral therapyAcute treatmentBinge-eating frequencyInitial interventionTherapist-led cognitive behavioural therapyInitial pharmacological treatmentTreat remission ratesEvidence-based treatmentsSingle-site trialAcute efficacyRemission rateAdult patientsInitial treatmentPharmacological treatmentPatientsPosttreatment assessmentBehavioral treatmentSufficient benefitTherapyDisordersInterventionTreatmentPharmacotherapy
2022
Predictors of abstinence, no heavy drinking days, and a 2‐level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study
Wallach JD, Gueorguieva R, Phan H, Witkiewitz K, Wu R, O'Malley SS. Predictors of abstinence, no heavy drinking days, and a 2‐level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study. Alcohol Clinical And Experimental Research 2022, 46: 1331-1339. PMID: 35616436, PMCID: PMC9887652, DOI: 10.1111/acer.14877.Peer-Reviewed Original ResearchConceptsHeavy drinking daysWeeks of treatmentAlcohol use disorderDependence Scale scoresDrinking daysScale scoreDays abstinentPredictors of abstinenceConsecutive weeksUse disordersDrinking levelsCOMBINE StudyOlder subjectsRandomized placebo-controlled trialPlacebo-controlled trialEfficacy of naltrexoneMultiple patient characteristicsTrials of medicationsBehavioral intervention studyPatient characteristicsFuture trialsBaseline variablesCombined PharmacotherapiesYoung subjectsComplete abstinenceClinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic
Bondar J, Morrow C, Gueorguieva R, Brown M, Hawrilenko M, Krystal JH, Corlett PR, Chekroud AM. Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic. JAMA Network Open 2022, 5: e2216349. PMID: 35679044, PMCID: PMC9185188, DOI: 10.1001/jamanetworkopen.2022.16349.Peer-Reviewed Original ResearchConceptsMental health programsHealth programsCohort studyLarge clinical effect sizesPatient Health Questionnaire-9Common mental health conditionsSheehan Disability ScaleClinical effect sizeMental health conditionsMental health symptomsCost of treatmentGeneralized anxiety disorderMental health difficultiesMental health benefitsWorkplace wellness programsCare navigationClinical improvementPrimary outcomeClinical benefitQuestionnaire-9Disability ScaleMedication managementLeast moderate anxietyMixed-effects regressionPerson psychotherapySensitivity, specificity, and tolerability of the BACTrack Skyn compared to other alcohol monitoring approaches among young adults in a field‐based setting
Ash GI, Gueorguieva R, Barnett NP, Wang W, Robledo DS, DeMartini KS, Pittman B, Redeker NS, O’Malley S, Fucito LM. Sensitivity, specificity, and tolerability of the BACTrack Skyn compared to other alcohol monitoring approaches among young adults in a field‐based setting. Alcohol Clinical And Experimental Research 2022, 46: 783-796. PMID: 35567595, PMCID: PMC9179100, DOI: 10.1111/acer.14804.Peer-Reviewed Original ResearchDevelopment of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans
De Aquino JP, DeVito EE, Xie C, Meyerovich J, Parida S, Gueorguieva R, Sofuoglu M. Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans. Psychopharmacology 2022, 239: 2809-2818. PMID: 35554617, DOI: 10.1007/s00213-022-06162-0.Peer-Reviewed Original ResearchImpact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science
De Aquino JP, MacLean RR, Gueorguieva R, DeVito EE, Eid T, Sofuoglu M. Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. Addiction Biology 2022, 27: e13161. PMID: 35229960, PMCID: PMC8903077, DOI: 10.1111/adb.13161.Peer-Reviewed Original ResearchConceptsAbuse potentialPositive subjective drug effectsSubjective drug effectsHuman laboratory studiesPositive subjective effectsAttention functionSmoking urgesOvernight abstinencePotential therapeutic effectsEffects of nicotineHeart rate increaseDelivery rateDependent smokersExperimental sessionsSubjective effectsNicotine dependenceIntravenous nicotineBlood pressureSaline infusionAcute effectsTherapeutic effectHeart rateDrug effectsAcute responseCrossover design
2021
Dynamic structural equation modeling of the relationship between alcohol habit and drinking variability
DeMartini KS, Gueorguieva R, Taylor JR, Krishnan-Sarin S, Pearlson G, Krystal JH, O'Malley SS. Dynamic structural equation modeling of the relationship between alcohol habit and drinking variability. Drug And Alcohol Dependence 2021, 233: 109202. PMID: 35151022, PMCID: PMC10046111, DOI: 10.1016/j.drugalcdep.2021.109202.Peer-Reviewed Original ResearchDopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchConceptsCortical dopamine neurotransmissionPositive allosteric modulationImportant therapeutic targetPF-06412562Dopaminergic receptorsD1R stimulationDA levelsTolerable dosesLevel of stimulationDopamine neurotransmissionReceptor stimulationTherapeutic targetPartial agonistCognitive deficitsBiased agonismFull agonismTarget engagementAllosteric modulationNew drugsStimulationPoor bioavailabilitySchizophreniaOptimal stimulationDrugsExpression levelsIndividual Differences in the Associations Between Risk Factors for Alcohol Use Disorder and Alcohol Use-Related Outcomes
Haeny AM, Gueorguieva R, Jackson A, Morean ME, Krishnan-Sarin S, DeMartini KS, Pearlson GD, Anticevic A, Krystal JH, O’Malley S. Individual Differences in the Associations Between Risk Factors for Alcohol Use Disorder and Alcohol Use-Related Outcomes. Psychology Of Addictive Behaviors 2021, 35: 501-513. PMID: 34110841, PMCID: PMC9211405, DOI: 10.1037/adb0000733.Peer-Reviewed Original ResearchExamining depression scores as predictors and moderators of treatment outcomes in patients with binge‐eating disorder
Grilo CM, Gueorguieva R, Pittman B. Examining depression scores as predictors and moderators of treatment outcomes in patients with binge‐eating disorder. International Journal Of Eating Disorders 2021, 54: 1555-1559. PMID: 34137474, DOI: 10.1002/eat.23569.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyBinge-eating disorderEvidence-based psychological interventionsDepression scoresEating Disorder PsychopathologyBinge-eating frequencyPredictors/moderatorsModerators of responseElevated depression scoresPsychological interventionsBWL interventionModeratorTreatment outcomesBaseline depression scoresLong-term outcomesBWLModerate outcomeFindings reinforceDepressionScoresDisordersInterventionPsychopathologyEarly changesPatientsThe effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials
Haeny AM, Gueorguieva R, Montgomery L, Bold KW, Fucito LM, Wu R, Muvvala SB, Zweben A, O'Malley SS. The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials. Addictive Behaviors 2021, 122: 106970. PMID: 34216871, PMCID: PMC9426655, DOI: 10.1016/j.addbeh.2021.106970.Peer-Reviewed Original ResearchConceptsEffects of vareniclineAlcohol use disorderCigarette smokingClinical trialsUse disordersWhite adultsEfficacy of vareniclineNumber of drinksVareniclineSmokingPrimary analysisAlcohol treatmentSecondary analysisAlcohol useTrialsBlack participantsDrinking outcomesLinear mixed modelsAdultsWhite peopleWhite participantsMixed modelingCigarettesDisordersTreatmentMapping data‐driven individualized neurobehavioral phenotypes in heavy alcohol drinkers
DeMartini KS, Gueorguieva R, Pearlson G, Krishnan‐Sarin S, Anticevic A, Ji LJ, Krystal JH, O’Malley S. Mapping data‐driven individualized neurobehavioral phenotypes in heavy alcohol drinkers. Alcohol Clinical And Experimental Research 2021, 45: 841-853. PMID: 33605439, DOI: 10.1111/acer.14580.Peer-Reviewed Original ResearchConceptsConfirmatory factor analysisIncentive salienceNeurofunctional domainsAlcohol use disorderExecutive functionLatent factorsPhysical neglectSelf-report measuresChildhood emotional abuseUse disordersChildhood physical neglectEarly life stressSignificant predictorsMultiple significant predictorsMultiple causes modelCurrent AUDNegative emotionalityAddiction developmentEmotional abuseChildhood neglectFactor structureDrinking frequencySalienceCause modelFactor analysisThreshold dose for intravenous nicotine self-administration in young adult non-dependent smokers
MacLean RR, DeVito EE, Eid T, Parida S, Gueorguieva R, Sofuoglu M. Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers. Psychopharmacology 2021, 238: 2083-2090. PMID: 33796907, PMCID: PMC8715498, DOI: 10.1007/s00213-021-05833-8.Peer-Reviewed Original ResearchConceptsDose of nicotineNicotine reinforcementHigh doseSubjective effectsHuman laboratory studiesYoung adult smokersNicotine self-administration modelNon-dependent smokersOvernight nicotine abstinenceEffects modelSelf-administration modelSelf-administration procedureNicotine doseAdult smokersMethodsYoung adultsObjectivesThe current studyNicotine abstinenceNicotine addictionHigh dosesLow dosesPlaceboThreshold doseReinforcement thresholdTobacco productsDose